Scarica l'app Stockscreener
14.94
32.56%
3.67
Pre-mercato:
14.53
-0.41
-2.74%
Precedente Chiudi:
$11.27
Aprire:
$13.5
Volume 24 ore:
449.22K
Relative Volume:
4.02
Capitalizzazione di mercato:
$151.02M
Reddito:
$88.50M
Utile/perdita netta:
$-35.27M
Rapporto P/E:
-4.5336
EPS:
-3.2954
Flusso di cassa netto:
$-23.70M
1 W Prestazione:
+50.15%
1M Prestazione:
-0.86%
6M Prestazione:
+73.72%
1 anno Prestazione:
+57.50%
Intervallo 1D:
$13.32
$15.51
Intervallo di 1 settimana:
$9.432
$15.51
Portata 52W:
$3.436
$20.21
Biodesix Inc Stock (BDSX) Company Profile
Nome
Biodesix Inc
Settore
Industria
Telefono
303-417-0500
Indirizzo
919 WEST DILLON ROAD, LOUISVILLE
Compare BDSX vs TMO, DHR, IDXX, WAT, A
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BDSX
Biodesix Inc
|
14.94 | 151.02M | 88.50M | -35.27M | -23.70M | -3.2954 |
TMO
Thermo Fisher Scientific Inc
|
466.76 | 173.46B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
174.63 | 123.60B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.97 | 44.71B | 4.30B | 1.06B | 1.04B | 13.08 |
WAT
Waters Corp
|
342.75 | 33.65B | 3.17B | 642.63M | 516.49M | 10.77 |
A
Agilent Technologies Inc
|
117.53 | 33.21B | 7.07B | 1.29B | 993.00M | 4.5355 |
Biodesix Inc Stock (BDSX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-27 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2025-05-14 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-09-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-07-26 | Iniziato | Craig Hallum | Buy |
| 2024-05-13 | Iniziato | TD Cowen | Buy |
| 2024-05-03 | Iniziato | Lake Street | Buy |
| 2021-11-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-23 | Iniziato | BTIG Research | Buy |
| 2020-11-23 | Iniziato | Canaccord Genuity | Buy |
| 2020-11-23 | Iniziato | Morgan Stanley | Overweight |
| 2020-11-23 | Iniziato | William Blair | Outperform |
Mostra tutto
Biodesix Inc Borsa (BDSX) Ultime notizie
Biodesix Faces Mounting Reimbursement and Enforcement Risks as Evolving Payer Policies Threaten Revenue Stability - TipRanks
Biodesix Earnings Call Signals Strong Growth Momentum - TipRanks
Canaccord Genuity Group Issues Positive Forecast for Biodesix (NASDAQ:BDSX) Stock Price - MarketBeat
Biodesix touts ‘clear path toward profitability’ - BizWest
William Blair Maintains Biodesix(BDSX.US) With Buy Rating - Moomoo
Biodesix Inc. 10-Q Q1 2026: Financial Statements, Risk Factors, and Management Analysis - Minichart
Biodesix stock price target raised to $22 by Canaccord on revenue growth - Investing.com
Biodesix, Inc. (NASDAQ:BDSX) Q1 2026 Earnings Call Transcript - Insider Monkey
Biodesix, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Biodesix Q1 Earnings Call Highlights - MarketBeat
Biodesix (BDSX) Q1 2026 Earnings Transcript - The Globe and Mail
BDSX: Q1 revenue up 42% year-over-year, with raised 2026 guidance and margin expansion - TradingView
Earnings call transcript: Biodesix Q1 2026 shows revenue growth, stock steady - Investing.com
Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Biodesix Inc (NASDAQ:BDSX) Q1 Results Smash Estimates, Shares Jump on Raised Guidance - ChartMill
Biodesix (NASDAQ:BDSX) Announces Earnings Results - MarketBeat
Q1 2026 Biodesix Inc Earnings Call Transcript - GuruFocus
Biodesix Announces First Quarter 2026 Results and Highlights - The Manila Times
Biodesix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Biodesix (NASDAQ: BDSX) grows Q1 2026 revenue and trims loss - Stock Titan
Biodesix lifts 2026 forecast after Q1 revenue hits $25.6M - Stock Titan
Strong Q1 for Biodesix (Nasdaq: BDSX) with 42% revenue growth - Stock Titan
MSN Money - MSN
Biodesix Inc expected to post a loss of $1.10 a shareEarnings Preview - TradingView
Earnings To Watch: Biodesix Inc (BDSX) Reports Q1 2026 Result - GuruFocus
Earnings Preview: Biodesix to Report Financial Results Post-market on May 04 - Moomoo
Biodesix (NASDAQ: BDSX) holder AIGH reports 7.7% ownership - Stock Titan
Wall Street analysts think Biodesix (BDSX) could surge 111.62%: Read this before placing a bet - MSN
BDSX Stock Price, Quote & Chart | BIODESIX INC (NASDAQ:BDSX) - ChartMill
Wall Street analysts see an 86.45% upside in Biodesix (BDSX): Can the stock really move this high? - MSN
Biodesix (BDSX) to Release Earnings on Monday - MarketBeat
Biodesix, Inc. (NASDAQ:BDSX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Biodesix skyrockets 43%, expects FY revenue to beat guidance - MSN
BDSX Price Today: Biodesix, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Are Medical Stocks Lagging Aura Biosciences (AURA) This Year? - Yahoo Finance
BDSX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Biodesix (BDSX) Options Set for Delisting on April 20 - GuruFocus
Biodesix to Report First Quarter 2026 Financial Results on May 4, 2026 - 富途牛牛
Biodesix to highlight novel diagnostic test discovery and pipeline development at AACR 2026 - SelectScience
Biodesix plans May 4 Q1 results release, 4:30 p.m. ET webcast - Stock Titan
How Recent Shifts Are Reframing The Biodesix (BDSX) Investment Story - Yahoo Finance
Aberdeen Group plc Takes $1.78 Million Position in Biodesix, Inc. $BDSX - MarketBeat
Biodesix (NASDAQ: BDSX) outlines 2026 virtual meeting, board and pay votes - Stock Titan
Employees put Biodesix on USA TODAY's Top Workplaces list for a third year - Stock Titan
Rate Hike: Can Biodesix Inc expand into new marketsQuarterly Portfolio Report & Accurate Buy Signal Notifications - baoquankhu1.vn
Biodesix, Inc. (BDSX) stock price, news, quote and history - Yahoo Finance UK
Biodesix Unveils Novel Diagnostic Test at AACR 2026 - National Today
Biodesix Announces AACR 2026 Posters and Presentations, Highlighting Novel Diagnostic Test Discovery & Pipeline Development - The Manila Times
Biodesix to Showcase Advances in Diagnostic Solutions at AACR Annual Meeting 2026 - Quiver Quantitative
Cancer test developer Biodesix brings 7 studies to AACR meeting - Stock Titan
Biodesix Inc Azioni (BDSX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.63%
0.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):